DHR · earnings call history
Danaher Q2 FY26 — Strong Growth Acceleration and Raised Full-Year EPS Guidance
Read the briefDanaher Q1 FY26 — Bioprocessing recovery and cost execution offset a soft respiratory season
Read the briefDanaher Q4 FY25 — Strong Finish Driven by Bioprocessing and Diagnostics Momentum
Read the briefBrowse all US companies on the earnings-call register.